Previous
Pause
Siguiente
Skip to Navigation
↓
Congresos
Año
Año
Año
-Año
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Investigador
Todos
usuario_prueba
Almeida e Silva, Filomena Augusta
Angás Pajas, Jorge
Arenal , Raúl
Baptista , Pedro Miguel
Bernechea Navarro, María
Bover Arbós, Pere
Calvo Lacosta, Jorge Hugo
Carstensen , Hans-Heinrich
Cazcarro Castellano, Ignacio
Cobarrubias Baglietto, Sebastián Felipe
Espina Cadena, Laura
Fernandez Antoran, David
Gil Hernández, Vanesa
Gracia Lostao, Ana Isabel
Gurauskis , Jonas
Gómez Candón, David
Hernández Ainsa, Silvia
Hernández Latas, José Antonio
Hurtado Guerrero, Ramón
Jiménez Schuhmacher, Alberto
Juarez-Perez , Emilio J.
Köhler , Ralf
Millán Gasca, Javier
Montiel , Manuel
Muñoz Soro, José Félix
Olmo , Jose
Ordovás Vidal, Laura
Philippidis , George
Ramón García, Santiago
Roque , Carla
Schoorlemmer , Jon
Sola , Daniel
Stavridis , Stelios
Sánchez Martínez, Diego
Velasco Lozano, Susana
Íñiguez Dieste, David
Título
Título
Año
Hollow fiber system for TB: optimization studies with Moxifloxacin
2022
OPTIKA – a new high content drug combination dynamic assay / Hollow-fibre models
2022
A new weapon against Mycobacterium abscessus
2022
In vitro time-kill assays of amoxicillin/clavulanate in combination with rifampicin/clarithromycin against Mycobacterium ulcerans
2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay
2022
Implementing best practises on data generation and reporting of Mycobacterium tuberculosis time kill assays: a case study of standardized protocol within the ERA4TB consortium
2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial
2022
The veterinary anthelmintic selamectin inhibits the mycobacterial DprE1 enzyme
2022
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic
2022
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells
2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial
2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial
2022
Study of in vitro and in vivo activity of a novel compound against Mycobacterium abscessus for the treatment of cystic fibrosis infections
2022
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens
2022
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU)
2022
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative
2022
OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations
2022
In vitro synergy screens of FDA-approved drugs combined with last-line antibiotics reveal new bactericidal combinations against Klebsiella pneumoniae
2022
Hollow fiber system for tuberculosis setting up at university of Zaragoza
2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial
2022
Páginas
1
2
3
4
siguiente ›
última »